Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.48 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540332 | 0.81 | PIK3CD (0.64) | PIK3CDPIK3CBPIK3CGASH1LAHR | |
| SCHEMBL5831166 | 0.80 | PRKCI (0.61) | PIK3CDPIK3CBPIK3CGASH1LAHR | |
| SCHEMBL31735956 | 0.80 | PRKCI (0.61) | PIK3CDPIK3CBPIK3CGASH1LAHR | |
| SCHEMBL1840342 | 0.77 | IGF1R (0.60) | PIK3CDPIK3CBPIK3CGGSK3BKDR | |
| SCHEMBL26259990 | 0.76 | BRD4 (0.45) | MTORABL1 | |
| SCHEMBL31675815 | 0.76 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGASH1LAHR | |
| SCHEMBL5831286 | 0.76 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGASH1LAHR | |
| SCHEMBL10945814 | 0.75 | PIK3CD (0.75) | PIK3CDPIK3CBPIK3CGASH1LAHR | |
| SCHEMBL28228155 | 0.74 | HSD17B10 (0.59) | PIM1GSK3BABL1 | |
| SCHEMBL24785626 | 0.74 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGASH1LAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283922-A | Preparation method of 4-indolopyrimidine biaryl compound | 新天地医药技术研究院(郑州)有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | PIK3CD 218/4885PIK3CB 280/4885PIK3CG 359/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | PIK3CD 218/4885PIK3CB 280/4885PIK3CG 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.